Prelude Therapeutics (PRLD) Common Equity (2019 - 2026)
Prelude Therapeutics (PRLD) posted Common Equity of $60.2 million for Q1 2026, down 12.32% sequentially from $68.6 million in Q4 2025, and down 41.67% YoY from $103.2 million in Q1 2025.
Prelude Therapeutics (PRLD) Common Equity (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Common Equity for 8 years, with the latest figure at $60.2 million in Q1 2026.
- Quarterly Common Equity fell 41.67% year-over-year to $60.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.2 million (down 41.67% YoY) and the FY2025 annual result came in at $68.6 million, down 47.79% from the prior year.
- Common Equity declined to $60.2 million in Q1 2026 per PRLD's latest filing, from $68.6 million in the prior quarter.
- Over five years, Common Equity peaked at $262.1 million in Q2 2023 and troughed at $58.5 million in Q3 2025.
- A 5-year average of $169.1 million and a median of $182.3 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity climbed 21.31% in 2023, then plunged 62.58% in 2025.
- Over 5 years, Common Equity stood at $195.4 million in 2022, then advanced by 21.31% to $237.1 million in 2023, then tumbled by 44.55% to $131.5 million in 2024, then tumbled by 47.79% to $68.6 million in 2025, then declined by 12.32% to $60.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $60.2 million, $68.6 million, and $58.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 133.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.73 Mn |
| Mar 31, 2026 | 60.18 Mn |
| Dec 31, 2025 | 68.64 Mn |
| Sep 30, 2025 | 58.53 Mn |
| Jun 30, 2025 | 75.84 Mn |
| Mar 31, 2025 | 103.18 Mn |
| Dec 31, 2024 | 131.46 Mn |
| Sep 30, 2024 | 156.43 Mn |
| Jun 30, 2024 | 182.28 Mn |
| Mar 31, 2024 | 210.73 Mn |
| Dec 31, 2023 | 237.09 Mn |
| Sep 30, 2023 | 238.26 Mn |
| Jun 30, 2023 | 262.06 Mn |
| Mar 31, 2023 | 175.30 Mn |
| Dec 31, 2022 | 195.44 Mn |
| Sep 30, 2022 | 217.41 Mn |
| Jun 30, 2022 | 240.84 Mn |
| Mar 31, 2022 | 261.81 Mn |
| Dec 31, 2021 | 285.90 Mn |
| Sep 30, 2021 | 311.24 Mn |